<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pharmateca</journal-id><journal-title-group><journal-title xml:lang="en">Pharmateca</journal-title><trans-title-group xml:lang="ru"><trans-title>Фарматека</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2073-4034</issn><issn publication-format="electronic">2414-9128</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">278837</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">EFFECT OF OMACOR ON THE MORPHOLOGICAL STATUS OF VENOUS BYPASSES IN PATIENTS WITH CORONARY HEART DISEASE AFTER MYOCARDIAL REVASCULARIZATION</article-title><trans-title-group xml:lang="ru"><trans-title>ВЛИЯНИЕ ОМАКОРА НА МОРФОЛОГИЧЕСКОЕ СОСТОЯНИЕ ВЕНОЗНЫХ ШУНТОВ У БОЛЬНЫХ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА ПРИ РЕВАСКУЛЯРИЗАЦИИ МИОКАРДА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Panov</surname><given-names>Aleksey Vladimirovich</given-names></name><name xml:lang="ru"><surname>Панов</surname><given-names>Алексей Владимирович</given-names></name></name-alternatives><bio xml:lang="ru"><p>ФГУ Федеральный центр сердца, крови и эндокринологии им. В.А. Алмазова</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mitrofanova</surname><given-names>Lyubov' Borisovna</given-names></name><name xml:lang="ru"><surname>Митрофанова</surname><given-names>Любовь Борисовна</given-names></name></name-alternatives><bio xml:lang="ru"><p>ФГУ Федеральный центр сердца, крови и эндокринологии им. В.А. Алмазова</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kozulin</surname><given-names>Vikentiy Yur'evich</given-names></name><name xml:lang="ru"><surname>Козулин</surname><given-names>Викентий Юрьевич</given-names></name></name-alternatives><bio xml:lang="ru"><p>ФГУ Федеральный центр сердца, крови и эндокринологии им. В.А. Алмазова</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Usova</surname><given-names>Elena Anatol'evna</given-names></name><name xml:lang="ru"><surname>Усова</surname><given-names>Елена Анатольевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>ФГУ Федеральный центр сердца, крови и эндокринологии им. В.А. Алмазова</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Alugishvili</surname><given-names>Marianna Zakhar'evna</given-names></name><name xml:lang="ru"><surname>Алугишвили</surname><given-names>Марианна Захарьевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>ФГУ Федеральный центр сердца, крови и эндокринологии им. В.А. Алмазова</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tyan</surname><given-names>Natal'ya Afanas'evna</given-names></name><name xml:lang="ru"><surname>Тян</surname><given-names>Наталья Афанасьевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>ФГУ Федеральный центр сердца, крови и эндокринологии им. В.А. Алмазова</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Panov</surname><given-names>-</given-names></name><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Mitrofanova</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Kozulin</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Usova</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Alugivishvili</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Tyan</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ФГУ Федеральный центр сердца, крови и эндокринологии им. В.А. Алмазова</institution></aff></aff-alternatives><aff id="aff2"><institution></institution></aff><pub-date date-type="pub" iso-8601-date="2011-03-15" publication-format="electronic"><day>15</day><month>03</month><year>2011</year></pub-date><volume>18</volume><issue>5</issue><issue-title xml:lang="en">NO5 (2011)</issue-title><issue-title xml:lang="ru">№5 (2011)</issue-title><fpage>111</fpage><lpage>115</lpage><history><date date-type="received" iso-8601-date="2023-02-23"><day>23</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2011, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2011, ООО «Бионика Медиа»</copyright-statement><copyright-year>2011</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/2073-4034/article/view/278837">https://journals.eco-vector.com/2073-4034/article/view/278837</self-uri><abstract xml:lang="en"><p>The increasing number of aorto-coronary bypass grafts surgeries demands to develop new options and methods of treating this category of patients. According to up to date concepts patients after CABG are exposed to different risk factors and needed to be treated using modern approaches to reduce the progression of coronary artery disease and its complications. New drugs such as ω-3 unsaturated fatty acids are known to improve the outcomes after performed CABG surgery. This article analyses the place of Omacor in the complex treatment of these patients before CABG. According to performed study the therapy of omacor 2 g daily during 14 days before surgery was associated with reduction of intimal hyperplasia of venous conduits. In addition, the number of smooth muscle cells and proliferation index were also significantly reduced according to performed immunochemistry investigation. Based on this study, antiproliferative activity of Omacor may improve the viability of venous conduits in long terms.</p></abstract><trans-abstract xml:lang="ru"><p>Увеличение количества операций коронарного шунтирования сопряжено с необходимостью активного внедрения методов, улучшающих ближайшие и отдаленные результаты этих вмешательств. В последние годы проведен ряд исследований, позволяющих рассматривать ω-3 полиненасыщенные жирные кислоты в качестве дополнительного средства для улучшения исходов оперативного лечения ишемической болезни сердца. В статье представлены результаты применения лекарственного препарата ω-3 полиненасыщенных жирных кислот Омакора у больных ишемической болезнью сердца непосредственно перед хирургическим вмешательством. Установлено, что Омакор в дозе 2 г/сут в течение 14 дней перед операцией приводит к уменьшению гиперплазии интимы, снижению числа гладкомышечных клеток в медии, а также индекса пролиферации по данным иммуногистохимического анализа в участках большой подкожной вены, выделенных для коронарного анастомоза. Предполагается, что антипролиферативные эффекты Омакора могут оказывать положительное влияние в отношении отдаленной жизнеспособности аутовенозных шунтов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Coronary artery disease</kwd><kwd>coronary artery bypass grafts surgery</kwd><kwd>venous conduits</kwd><kwd>omacor</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ишемическая болезнь сердца</kwd><kwd>коронарное шунтирование</kwd><kwd>аутовенозный шунт</kwd><kwd>ω-3 полиненасыщенные жирные кислоты</kwd><kwd>Омакор</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Беленков Ю.Н., Акчурин Р.С., Савченко А.П. Рентгеноморфологическая характеристика поражения шунтов у больных ишемической болезнью сердца после операции аортокоронарного шунтирования // Кардиология 2000. № 1. С. 6-12.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Ардашев А.В., Коков Л.С., Синицын В.Е. Обследование и рентгенохирургическое лечение больных после операции аортокоонарного шунтирования. Медпрактика-М., 2007.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Fitzgibbon GM, Kafka HP, Leach AJ. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5065 grafts related to survival and reoperation in 1388 patients during 25 years. J Am Coll Cardiol 1996;28:616-26.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Motwani JG, Topol EJ. Aortocoronary Saphenous Vein Graft Disease: Pathogenesis, Predisposition, and Prevention. Circulation 1998;97:916-31.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Hassantash SA, Bikdeli B, Kalantarian S, et al. Pathophysiology of Aortocoronary Saphenous Vein Bypass Graft Disease Asian Cardiovasc Thorac Ann 2008;16:331-36.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Donald S. Baim Percutaneous Treatment of Saphenous Vein Graft Disease. The ongoing challenge JACC 2003;42(8):1370-2.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Bang H, Dyerberg J, et al. The composition of the Eskimo food in Northwestern Greenland. Am J Clin Nutr 1980;33:2657-66.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Marchioli R, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the GISSI-Prevenzione. Circulation 2002;105:1897-1903.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Calo L, Bianconi L, Collivicchi F, et al. Рrevention of atrial fibrillation by n-3 polyunsaturated fatty acids after coronary artery bypass grafting. J Am Coll Cardiol 2005;45:1723-28.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Harris W, Reid K, Sands S, et al. Red blood cell omega-3 fatty acids in acute coronary syndrome patients. Circulation 2007;115(8):267.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Guidelines on myocardial revascularization The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Available at www.escardio.org/guidelines</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Панов А.В., Гордеев М.Л., Нильк Р.Я. и др. Применение омакора для предупреждения фибрилляции предсердий после хирургической реваскуляризации миокарда (Исследование АКСИОМА) // Артериальная гипертензия 2008. № 14. C. 162-64.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-68.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Balashov KE, Rottman JB, Weiner HL, et al. CCR5 and CXCR3 T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999;96:6873-78.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Balasingam V, Tejada-Berges T, Wright E, et al. Reactive astrogliosis in the neonatal mouse brain and its modulation by cytokines. J Neurosci 1994;14:846-56.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Balding CE, Howie AJ, Drake-Lee AB, et al. Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis. Clin Exp Immunol 2001;125:332-39.</mixed-citation></ref></ref-list></back></article>
